If that's the logic you are going to use. Then the Pancreatic trial is a bust. I think you are wrong. Bavituximab need's time to work and it should work well in Front Line Therapy! Wasn't that the argument for the Pancreatic trial? Why it did not work so well control vs Bavi MOS. Bavi would need a chance to work on the patients, who where not as advanced, as the ones in the Bavi arm. Remember the Bavi arm was skewed, had sicker patients(Cancer more advanced). As pointed out by poster's Bavi needed more time to train the body to fight back! So in theory Bavi should work well in Front Line.
Only problem! There are two variables compared to 2nd Line NSCLC Trial. Number one is a different drug and number two, patients have never been treated.
In the case of Bavituximab this should not matter!
News 
Market Data 
Discover 
